CLAIMS

1. A pharmaceutical composition comprising hemp extract and a carrier, wherein the hemp extract comprises:

cannabidiol; and

cannabidiolic acid;

wherein the ratio of cannabidiol to cannabidiolic acid is about 0.6:1 to about 1:0.6, and

wherein the carrier comprises biopolymer NF-971P and/or lecithin.

2. A pharmaceutical composition according to claim 1, wherein the hemp extract additionally comprises:

cannabigerolic acid;

Δ9-tetrahydrocannabinol; and

cannabichromene, optionally

wherein the hemp extract further comprises:

α-pinene;

β-myrcene;

β-pinene;

δ-limonene;

linalool;

β-caryophyllene;

α-humulene;

nerolidol 2;

guaiol;

caryophyllene oxide; and

α-bisabolol, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is insufficient to produce a psychotropic effect, and/or

wherein the ratio of Δ9-tetrahydrocannabinol to the other cannabinoids is about 1:25, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 1 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 0.5 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 0.3 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 0.2 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 0.1 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is about 0 mg/mL, and/or

wherein the hemp extract comprises:

about 1-10 mg/mL of cannabidiol;

about 1-10 mg/mL of cannabidiolic acid;

about 0.05-0.2 mg/mL cannabigerolic acid;

about 0.1-0.3 mg/mL Δ9-tetrahydrocannabinol; and

about 0.1-0.4 mg/mL cannabichromene, optionally

wherein the hemp extract comprises:

about 5 mg/mL of cannabidiol;

about 5 mg/mL of cannabidiolic acid;

about 0.11 mg/mL cannabigerolic acid;

about 0.25 mg/mL Δ9-tetrahydrocannabinol; and

about 0.27 mg/mL cannabichromene.

3. The pharmaceutical composition of claim 1 or 2, wherein the hemp extract comprises:

about 0.09-0.13% α-pinene;

about 0.23-0.44% β-myrcene;

about 0.04-0.09% β-pinene;

about 0.05-0.09% δ-limonene;

about 0.03-0.06% linalool;

about 0.04-0.07% β-caryophyllene;

about 0.02-0.04% α-humulene;

about 0.04-0.07% nerolidol 2;

about 0.02-0.04% guaiol;

about 0.04-0.08% caryophyllene oxide; and

about 0.01-0.04% α-bisabolol, optionally

wherein the hemp extract further comprises:

camphene;

β-ocimene;

eucalyptol;
isopulegol; and/or
nerolidol 1, further optionally,
wherein the hemp extract comprises:
about 0.02% camphene;
about 0.02-0.03% β-ocimene;
about 0.02-0.05% eucalyptol;
about 0.02% isopulegol; and/or
about 0.02-0.04% nerolidol 1.

4. The pharmaceutical composition of any one of claims 1-3, wherein the composition is formulated in a carrier, optionally
wherein the carrier is selected from the group consisting of linseed oil, olive oil, fish oil, salmon oil, coconut oil, catnip oil, sesame oil, MCT oil, and grapeseed oil, further optionally
wherein the carrier is grapeseed oil or catnip oil.

5. The pharmaceutical composition of any one of claims 1-4, wherein the composition comprises lecithin, optionally
wherein the lecithin is sunflower lecithin, further optionally
wherein the sunflower lecithin is up to 40%.

6. The pharmaceutical composition of any one of claims 1-5, wherein the composition further comprises NF-971P, optionally
wherein the NF-971P is up to 2% weight/volume ratio.

7. A pharmaceutical composition according to claim 1, wherein the hemp extract further comprises:
cannabigerolic acid;
Δ9-tetrahydrocannabinol; and
cannabichromene;
wherein the carrier comprises grapeseed oil and one of biopolymer NF-971P and lecithin, optionally
wherein the concentration of Δ9-tetrahydrocannabinol is insufficient to produce a psychotropic effect and/or

wherein the ratio of Δ9-tetrahydrocannabinol to the other cannabinoids is about 1:25, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 1 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 0.5 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 0.3 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 0.2 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is less than about 0.1 mg/mL, and/or

wherein the concentration of Δ9-tetrahydrocannabinol is about 0 mg/mL, and/or

wherein the hemp extract comprises:

about 1-10 mg/mL of cannabidiol;

about 1-10 mg/mL of cannabidiolic acid;

about 0.05-0.2 mg/mL cannabigerolic acid;

about 0.1-0.3 mg/mL Δ9-tetrahydrocannabinol; and

about 0.1-0.4 mg/mL cannabichromene, optionally

wherein the hemp extract comprises:

about 5 mg/mL of cannabidiol;

about 5 mg/mL of cannabidiolic acid;

about 0.11 mg/mL cannabigerolic acid;

about 0.25 mg/mL Δ9-tetrahydrocannabinol; and

about 0.27 mg/mL cannabichromene, and/or

wherein the hemp extract comprises:

α-pinene;

β-myrcene;

β-pinene;

δ-limonene;

linalool;

β-caryophyllene;

α-humulene;

nerolidol 2;

guaiol;

caryophyllene oxide; and

α-bisabolol, optionally

wherein the hemp extract comprises:

about 0.09-0.13% α-pinene;

about 0.23-0.44% β-myrcene;

about 0.04-0.09% β-pinene;

about 0.05-0.09% δ-limonene;

about 0.03-0.06% linalool;

about 0.04-0.07% β-caryophyllene;

about 0.02-0.04% α-humulene;

about 0.04-0.07% nerolidol 2;

about 0.02-0.04% guaiol;

about 0.04-0.08% caryophyllene oxide; and

about 0.01-0.04% α-bisabolol, and/or

wherein the hemp extract further comprises:

camphene;

β-ocimene;

eucalyptol;

isopulegol; and/or

nerolidol 1, optionally

wherein the hemp extract comprises:

about 0.02% camphene;

about 0.02-0.03% β-ocimene;

about 0.02-0.05% eucalyptol;

about 0.02% isopulegol; and/or

about 0.02-0.04% nerolidol 1.

8. A dosage form comprising any of the pharmaceutical compositions of any one of claims 1-7 and one or more pharmaceutically acceptable additives, flavoring agents, surfactants, and adjuvants.

9. The dosage form of claim 8, wherein the flavoring agent is selected from the group consisting of peppermint oil, mango extract, beef, poultry, and seafood, or

formulated as a sublingual spray, or

formulated as a water or alcohol soluble solution, or a cream for transdermal application, or

formulated as a gel for buccal or mucosal administration, or

formulated as a powder, or

formulated as a solution for subcutaneous injection, or

formulated as a tablet, or

formulated as a capsule, or

formulated as a hard chewable or

formulated as a soft chewable or

wherein the composition is formulated for administration using a nebulizer, or

wherein the composition is formulated for administration using a pet collar, or

wherein the composition is formulated as a chew for oral administration, optionally

where the chew is produced using cold extrusion, further optionally

wherein the weight of the chew is about 0.5-10 g, further optionally

wherein the weight of the chew is about 4 g, about 6 g, about 9 g, or about 10 g, further optionally

wherein the weight of the chew is about 4 g, further optionally

wherein the chew comprises:

about 7 mg of cannabidiol;

about 6 mg of cannabidiolic acid;

about 0.12 mg cannabigerolic acid;

about 0.32 mg Δ9-tetrahydrocannabinol; and

about 0.36 mg cannabichromene.

10. The dosage form of claim 8, formulated in a carrier for oral administration, optionally

wherein the carrier is selected from the group consisting of linseed oil, olive oil, fish oil, salmon oil, coconut oil, catnip oil, sesame oil, MCT oil, and grapeseed oil, further optionally

wherein the carrier is grapeseed oil, or catnip oil.

11. The dosage form of claim 8, formulated for inhalation.

12. Use of a hemp extract in the manufacture of a pharmaceutical composition for the treatment of epilepsy in a veterinary subject in need thereof, wherein a therapeutically effective amount of the pharmaceutical composition comprising the hemp extract and a carrier is to be administered to the veterinary subject, and wherein the hemp extract comprises:

cannabidiol; and

cannabidiolic acid;

wherein the ratio of cannabidiol to cannabidiolic acid is about 0.6:1 to about 1:0.6.

13. Use of a hemp extract in the manufacture of a pharmaceutical composition for the treatment of cancer in a veterinary subject in need thereof, wherein a therapeutically effective amount of the pharmaceutical composition comprising the hemp extract and a carrier is to be administered to the veterinary subject, and wherein the hemp extract comprises:

cannabidiol; and

cannabidiolic acid;

wherein the ratio of cannabidiol to cannabidiolic acid is about 0.6:1 to about 1:0.6.

14. Use of a hemp extract in the manufacture of a pharmaceutical composition for improving quality of life in a veterinary subject with cancer, wherein a therapeutically effective amount of the pharmaceutical composition comprising the hemp extract and a carrier is to be administered to the veterinary subject, and wherein the hemp extract comprises:

cannabidiol; and

cannabidiolic acid;

wherein the ratio of cannabidiol to cannabidiolic acid is about 0.6:1 to about 1:0.6.